CO5580754A2 - Composicion farmaceutica a base de un agonista de receptor adrenergico beta-3 y un inhibidor de la reabsorcion de se- rotonina y/o norepinefrina - Google Patents

Composicion farmaceutica a base de un agonista de receptor adrenergico beta-3 y un inhibidor de la reabsorcion de se- rotonina y/o norepinefrina

Info

Publication number
CO5580754A2
CO5580754A2 CO05062906A CO05062906A CO5580754A2 CO 5580754 A2 CO5580754 A2 CO 5580754A2 CO 05062906 A CO05062906 A CO 05062906A CO 05062906 A CO05062906 A CO 05062906A CO 5580754 A2 CO5580754 A2 CO 5580754A2
Authority
CO
Colombia
Prior art keywords
component
ethyl
composition according
dimethylphenyloxy
hydroxyphenyl
Prior art date
Application number
CO05062906A
Other languages
English (en)
Spanish (es)
Inventor
Wienrich Marion
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of CO5580754A2 publication Critical patent/CO5580754A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
CO05062906A 2002-11-27 2005-06-27 Composicion farmaceutica a base de un agonista de receptor adrenergico beta-3 y un inhibidor de la reabsorcion de se- rotonina y/o norepinefrina CO5580754A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02026546A EP1424079A1 (en) 2002-11-27 2002-11-27 Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine

Publications (1)

Publication Number Publication Date
CO5580754A2 true CO5580754A2 (es) 2005-11-30

Family

ID=32241298

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05062906A CO5580754A2 (es) 2002-11-27 2005-06-27 Composicion farmaceutica a base de un agonista de receptor adrenergico beta-3 y un inhibidor de la reabsorcion de se- rotonina y/o norepinefrina

Country Status (22)

Country Link
US (2) US20050261328A1 (enExample)
EP (4) EP1424079A1 (enExample)
JP (2) JP2006509751A (enExample)
KR (1) KR20050088295A (enExample)
CN (1) CN1717230A (enExample)
AT (1) ATE399005T1 (enExample)
AU (2) AU2003285312A1 (enExample)
BR (1) BR0316535A (enExample)
CA (2) CA2507266A1 (enExample)
CO (1) CO5580754A2 (enExample)
DE (1) DE50310046D1 (enExample)
EA (1) EA009781B1 (enExample)
EC (1) ECSP055814A (enExample)
ES (1) ES2309371T3 (enExample)
HR (1) HRP20050467A2 (enExample)
MX (1) MXPA05005483A (enExample)
NO (1) NO20053088L (enExample)
PL (1) PL376259A1 (enExample)
RS (1) RS20050392A (enExample)
UA (1) UA81931C2 (enExample)
WO (2) WO2004047830A2 (enExample)
ZA (1) ZA200503282B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2005042021A2 (de) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
DE10356112A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
CA2580170A1 (en) * 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Use of a beta-3 agonist for treating complaints of the prostate and the lower urogenital tract
EP1809591A1 (en) * 2004-10-26 2007-07-25 Kissei Pharmaceutical Co., Ltd. Synthesis of phenoxyacetic acid derivatives
CA2599158C (en) * 2005-02-25 2011-01-25 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
EP1769792A1 (de) * 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
US9440003B2 (en) * 2005-11-04 2016-09-13 Boston Scientific Scimed, Inc. Medical devices having particle-containing regions with diamond-like coatings
FR2895259B1 (fr) * 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires
JP5124286B2 (ja) * 2006-01-10 2013-01-23 キッセイ薬品工業株式会社 徐放性製剤およびその製造方法
BRPI0711606A2 (pt) * 2006-05-22 2012-02-14 Teva Pharma formulações de hidrocloreto de duloxetina de liberação retardada
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
WO2009066181A2 (en) * 2007-07-09 2009-05-28 Combino Pharm, S.L. Oral delayed-release duloxentine hydrochloride pellets
PT2216021E (pt) * 2007-11-02 2012-11-06 Astellas Pharma Inc Composição farmacêutica para tratar uma bexiga hiperactiva
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2010037849A1 (en) * 2008-10-02 2010-04-08 Laboratorios Del Dr. Esteve, S.A. Duloxetine enteric pellets
EP2363397A4 (en) * 2008-11-07 2012-07-11 Dainippon Sumitomo Pharma Co NEW USEFUL THERAPEUTICS FOR LOWER URINE-DISAPPEARING SURFACE SYMPTOM
EP2316432A1 (de) * 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
EP2377525A1 (en) * 2010-03-26 2011-10-19 Laboratorios del Dr. Esteve S.A. Duloxetine enteric pellets
WO2011122524A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US8642661B2 (en) * 2010-08-03 2014-02-04 Altherx, Inc. Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
KR20150020160A (ko) * 2012-02-09 2015-02-25 앨씨알엑스, 인크. 과민성 방광의 치료를 위한 무스카린 수용체 길항제 및 베타―3 아드레날린 수용체 작용제의 조합물
EP2897616A1 (en) * 2012-09-18 2015-07-29 TARIS Biomedical LLC Drug delivery systems and methods for treatment of bladder voiding dysfunction!and other lower urinary tract disorders by using trospium
PL224543B1 (pl) 2013-08-21 2017-01-31 Pabianickie Zakłady Farm Polfa Spółka Akcyjna Dojelitowa tabletka duloksetyny
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
KR20180069865A (ko) 2015-10-15 2018-06-25 듀크 유니버시티 방광 기능장애를 치료할 수 있는 상태-의존적인 말초 신경제어
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
US10543174B2 (en) 2016-04-25 2020-01-28 Synthon B.V. Modified release tablet composition comprising mirabegron
US20190307696A1 (en) 2016-04-25 2019-10-10 Synthon B.V. Tablets comprising mirabegron and solifenacin
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
PH30083A (en) * 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
IL104567A (en) * 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US6069176A (en) * 1995-10-26 2000-05-30 Mitsubishi-Tokyo Pharmaceuticals, Inc. Phenylethanolamine compounds useful as β 3 agonists, process for producing the same, and intermediates in the production of the same
ATE251608T1 (de) * 1996-01-10 2003-10-15 Asahi Chemical Ind Neue trizyklische verbindungen und arzneimittelzusammensetzungen die diese enthalten
JP2000506863A (ja) * 1996-03-11 2000-06-06 イーライ・リリー・アンド・カンパニー 間質性膀胱炎の治療または予防方法
CA2259012C (en) * 1996-07-19 2008-05-13 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
WO1998007445A1 (en) * 1996-08-19 1998-02-26 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
EA199900375A1 (ru) * 1996-11-14 1999-12-29 Пфайзер Инк. Способ получения замещенных пиридинов
WO1998022480A1 (en) * 1996-11-18 1998-05-28 Smithkline Beecham Plc Phosphorus containing aryloxy or arylthio propanolamine derivatives
JPH1112171A (ja) * 1997-06-19 1999-01-19 Nisshin Flour Milling Co Ltd 消化器疾患治療薬
ID24062A (id) * 1997-07-25 2000-07-06 Kissei Pharmaceutical Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing
US6346532B1 (en) * 1997-10-17 2002-02-12 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives or salts thereof
WO1999031045A1 (en) * 1997-12-18 1999-06-24 Kissei Pharmaceutical Co., Ltd. Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
EP1070046A1 (en) * 1998-04-06 2001-01-24 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
EP1072583B1 (en) * 1998-04-14 2004-09-01 Kissei Pharmaceutical Co., Ltd. 2-methylpropionic acid derivatives and medicinal compositions containing the same
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
CZ302630B6 (cs) * 1998-08-27 2011-08-10 Pharmacia & Upjohn Ab Farmaceutický prostredek obsahující tolterodin nebo tolterodinu príbuznou slouceninu
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
ES2228413T3 (es) * 1999-07-23 2005-04-16 Pfizer Products Inc. Productos intermedios y un procedimiento para producir agonistas de receptores beta-adrenergicos.
DE60021749T2 (de) * 1999-11-11 2006-04-20 Pfizer Health Ab Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
PT1257277E (pt) * 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
WO2001093683A1 (en) * 2000-06-07 2001-12-13 Watson Pharmaceuticals, Inc. Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin
US6514991B2 (en) * 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション
GB0102408D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Chemical compounds
EP1236723A1 (en) * 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
WO2002085871A2 (en) * 2001-04-04 2002-10-31 Wyeth Serotonergic agents with long-acting in vivo effects
WO2003035600A1 (en) * 2001-10-19 2003-05-01 Fujisawa Pharmaceutical Co., Ltd. Process for producing benzocycloheptene derivative
BR0206300A (pt) * 2001-11-05 2008-04-08 Upjohn Co composição farmacêutica para tratar distúrbio urinário em um mamìfero e uso
KR20050005410A (ko) * 2002-02-19 2005-01-13 파마시아 코포레이션 요실금 치료용으로서의 시클로옥시게나제 저해제 및항무스카린제의 용도

Also Published As

Publication number Publication date
HRP20050467A2 (en) 2006-06-30
NO20053088L (no) 2005-06-23
PL376259A1 (pl) 2005-12-27
AU2003285312A1 (en) 2004-06-18
BR0316535A (pt) 2005-10-04
CA2507343A1 (en) 2005-07-14
EA009781B1 (ru) 2008-04-28
RS20050392A (sr) 2007-04-10
DE50310046D1 (de) 2008-08-07
ES2309371T3 (es) 2008-12-16
EP1572181A2 (de) 2005-09-14
WO2004047838A3 (de) 2004-10-28
ECSP055814A (es) 2005-08-11
EP1640000A3 (de) 2007-01-17
US20090012161A9 (en) 2009-01-08
US20050261328A1 (en) 2005-11-24
AU2003289854A1 (en) 2004-06-18
EP1572181B1 (de) 2008-06-25
WO2004047838A2 (de) 2004-06-10
EP1424079A1 (en) 2004-06-02
MXPA05005483A (es) 2005-08-16
EA200500776A1 (ru) 2005-12-29
JP2006509752A (ja) 2006-03-23
EP1567149A2 (de) 2005-08-31
WO2004047830A2 (de) 2004-06-10
EP1640000A2 (de) 2006-03-29
UA81931C2 (uk) 2008-02-25
ATE399005T1 (de) 2008-07-15
CA2507266A1 (en) 2004-06-10
ZA200503282B (en) 2006-07-26
CN1717230A (zh) 2006-01-04
WO2004047830A3 (de) 2004-08-19
JP2006509751A (ja) 2006-03-23
KR20050088295A (ko) 2005-09-05
US20050261369A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
JP2006509751A5 (enExample)
US8716349B2 (en) Compositions and methods for the treatment of somatosensory disorders
US20190358199A1 (en) Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
AU2003289854A1 (en) Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents
CO5630034A2 (es) Procedimiento y composiciones farmaceuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
EA200100748A1 (ru) Ингибиторы обратного захвата моноаминов для лечения расстройств цнс
BRPI0413719A (pt) agonistas alfa2 não-sedativos
MA30556B1 (fr) COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE.
JP2005523334A5 (enExample)
PE20091322A1 (es) Composicion farmaceutica antimalarica
NO20061550L (no) Kombinasjon som innbefatter en alfa-2-delta ligand og en SSRO og/eller SNRI for behandling av depresjon og angstforstyrrelser
EP0996619A4 (en) TROPANE LOGA AND METHODS FOR INHIBITING THE TRANSPORT OF MONOAMINES
RU2012152922A (ru) Лечение психологических состояний с применением антагонистов м1-мускариновых рецепторов
CA2415154A1 (en) Modified release formulations of selective serotonin re-uptake inhibitors
CA2490638C (en) Combination therapy wherein a serotonin reuptake inhibitor is used
NO334448B1 (no) Farmasøytisk preparat som omfatter modafinil og et antidepressivt middel
US20160346249A1 (en) Use of amitifadine, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in methods and compositions with enhanced efficacy and reduced metabolic side effects and toxicity for treatment of depression and other central nervous system disorders and conditions affected by monoamine neurotransmitters
JP2009542820A5 (enExample)
HUP0303341A2 (hu) Monoamin-felvétel inhibitora és ezt tartalmazó gyógyszerkészítmények
JP2007513896A (ja) セロトニン再取り込み阻害剤およびヒスタミン３受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用
JP2007502785A (ja) うつ病の治療のためのセロトニン再取り込み阻害剤およびグリシントランスポーター１型阻害剤の併用
RU2009101143A (ru) Лечение психологических состояний с применением антаггонистов m1-мускариновых рецепторов
EA200600834A1 (ru) Пероральный антидепрессивный состав, включающий ацетилсалициловую кислоту для ускорения начала действия
TW200716554A (en) Novel pharmaceutical
TH88314A (th) การใช้ยาร่วมกันของ (สูตร)3 รีเซฟเตอร์อะโกนิสต์ และของตัวยับยั้งการดูดซึมกลับโมโนเอมีน, สารผสมทางเภสัชกรรมที่มีสารดังกล่าว และ การใช้สารดังกล่าวเพื่อการรักษา

Legal Events

Date Code Title Description
FC Application refused